Nina Y Wines, MB BS. Alan J Cooper, FACD. Michael P Wines, BMed.
Thalidomide in dermatology
Version of Record online: 29 NOV 2002
Australasian Journal of Dermatology
Volume 43, Issue 4, pages 229–240, November 2002
How to Cite
Wines, N. Y., Cooper, A. J. and Wines, M. P. (2002), Thalidomide in dermatology. Australasian Journal of Dermatology, 43: 229–240. doi: 10.1046/j.1440-0960.2002.00608.x
Manuscripts for this section should be submitted to Dr HC Chua.
- Issue online: 29 NOV 2002
- Version of Record online: 29 NOV 2002
- Submitted 17 November 2000; accepted 1 August 2002.
- Behçet's disease;
- chronic graft versus host disease;
- erythema nodosum leprosum;
- human immunodeficiency virus;
- peripheral neuropathy;
- practice guidelines;
- prurigo nodularis;
- systemic lupus erythematosus;
- toxic epidermal necrolysis
Thalidomide is an effective agent to treat over 25 seemingly unrelated dermatological conditions that have an inflammatory or autoimmune basis. The main side-effects of teratogenesis and peripheral neuropathy limit its use. Currently, in Australia no assurance is given as to the quality, safety and efficacy of thalidomide. The use of thalidomide for toxic epidermal necrolysis can lead to an increase in mortality, and its use as a prophylactic agent for the prevention of chronic graft-versus-host disease following bone marrow transplantation has raised more speculations as to the safety of this notorious drug. A review of the therapeutic indications for thalidomide in dermatology as well as the mechanisms of action and side-effects of this drug are presented. The current suggested guidelines for its use in clinical practice in Australia are discussed.